Company Overview

Odyssey Health, Inc. is a publicly traded biotechnology company operating in the biopharmaceutical and medical therapeutics industries, with a primary focus on developing novel treatments for central nervous system (CNS) disorders. The company’s core mission centers on addressing unmet medical needs in areas such as traumatic brain injury (TBI), concussion, and other neurological conditions through proprietary drug formulations and delivery technologies. Odyssey Health is quoted on the OTC Markets under the ticker ODYY.

The company’s strategy emphasizes the repurposing and reformulation of known pharmaceutical compounds combined with specialized delivery mechanisms intended to improve speed of onset and therapeutic effectiveness. Public disclosures indicate that Odyssey Health evolved from a concept-stage biotechnology venture into a development-stage company pursuing regulatory pathways for clinical-stage assets. However, detailed historical milestones and early-stage corporate evolution are data inconclusive based on available public sources.

Business Operations

Odyssey Health’s operations are centered on a single operating segment focused on drug development and commercialization for neurological indications. The company does not report diversified revenue-producing business units and remains primarily in the research and development phase, with activities including formulation development, preclinical evaluation, and regulatory planning. As of the most recent publicly available disclosures, the company does not report material commercial revenue.

The company’s business model relies on advancing internally developed therapeutic candidates toward regulatory approval, with future revenue generation expected from licensing, partnerships, or direct commercialization. Public records indicate no confirmed large-scale manufacturing operations, and reliance on third-party contractors for research, formulation, and testing appears likely. Specific technologies, proprietary assets, or controlled facilities beyond development-stage intellectual property are data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Odyssey Health positions itself within the neurological therapeutics niche, targeting indications with limited approved treatment options and high clinical demand, particularly acute brain injuries. Growth initiatives disclosed publicly focus on advancing lead drug candidates through clinical and regulatory milestones rather than near-term market expansion or diversification.

There is no verified evidence of completed material acquisitions, controlling investments in other companies, or ownership of a diversified subsidiary portfolio. Public disclosures do not confirm major strategic partnerships with large pharmaceutical companies. Any involvement in emerging technologies beyond CNS-focused drug delivery and formulation science is data inconclusive based on available public sources.

Geographic Footprint

Odyssey Health is headquartered in the United States, with corporate activities primarily based domestically. The company’s operational footprint appears concentrated in the U.S., consistent with its regulatory focus on U.S. clinical development and potential FDA approval pathways.

There is no verified disclosure of international offices, foreign subsidiaries, or material overseas operations. While future global commercialization is a stated long-term objective in general biotechnology industry practice, Odyssey Health’s current international market presence or investment influence is data inconclusive based on available public sources.

Leadership & Governance

Odyssey Health was founded by individuals with backgrounds in athletics, entrepreneurship, and health advocacy, reflecting a mission-driven leadership philosophy centered on addressing brain health and neurological injury. The company’s governance structure aligns with that of a small public biotechnology firm, with executive leadership overseeing strategy, capital formation, and clinical development priorities.

Key executive leadership publicly identified includes:

• Michael Redmond – Chief Executive Officer

Information regarding additional executive officers, board composition, or formal governance committees cannot be consistently verified across multiple independent public sources. As such, details beyond the CEO role are data inconclusive based on available public sources, and no further executive listings are provided to avoid unverified disclosure.